FutureLife Group growth accelerates with the strategic acquisition of the Bahceci Group in Turkey, Kosovo, Bulgaria and Bosnia & Herzegovina

FutureLife, one of the  major pan-European providers of fertility, IVF and genetics services, performing over 55,000 IVF cycles annually and backed by CVC Capital Partners ('CVC') and Hartenberg Holding ('Hartenberg'), is pleased to announce they reached agreement to acquire a stake in the Bahceci Group.

The Bahceci Group has spent nearly three decades at the forefront of fertility care, helping over 130,000 patients from more than 100 countries to fulfil their dreams of parenthood. With six clinics in Turkey, as well as international centres in Bosnia & Herzegovina, Bulgaria and Kosovo, Bahceci has earned a global reputation for excellence, combining compassionate patient care with outstanding clinical outcomes.
An ESHRE-certified Assisted Reproduction Centre, Bahceci performs over 18,000 IVF cycles annually.

The transaction completion is subject to fulfilment of conditions precedent including the Competition Board’s approval.

Francisco Lobbosco, CEO of FutureLife, commented:
"We are delighted to welcome Bahceci Group to the FutureLife family. This is a significant milestone for our group, as we continue to bring together the best fertility care providers across Europe and beyond. Bahceci’s size, reputation, and outstanding track record in patient care and clinical success will strengthen FutureLife’s presence across 12 countries and increase total annual IVF cycles to 73,000 per annum. Their world-class clinics, dedication to research, and impressive operational standards perfectly align with FutureLife’s mission to deliver exceptional care to every patient. Turkey is a highly strategic market in assisted reproduction, serving not only a large domestic population but also a growing number of international patients. We are excited to work alongside Bahceci’s talented teams and continue building on their incredible legacy.We look forward to welcoming the Bahceci teams into the FutureLife family as we continue to shape the future of reproductive medicine together.”

Hamdi Bahceci, CEO Bahceci Group commented:
“We are truly delighted to be joining the FutureLife family. This marks the beginning of an exciting new chapter for the Bahceci brand, building on our proud history and opening up significant opportunities for future growth and innovation. As part of a leading European group, we will be able to share our expertise, learn from outstanding clinics across the continent, and strengthen our commitment to delivering the highest standards of fertility care. Together with FutureLife, we look forward to expanding our reach, investing in new capabilities, and continuing to shape the future of reproductive medicine for patients around the world."

About FutureLife 
FutureLife is one of the major European providers of IVF, fertility treatments and related genetic services. With 40+ well-invested clinics, in 8 countries, employing more than 1,500 specialists performing in excess of 55,000 IVF cycles annually, as well as a series of gynaecological and surgical treatments.
In addition to its fertility clinic portfolio, FutureLife also operates two hospitals in the Czech Republic and the GNTLabs by GENNET, one of the largest and most modern genetic laboratories in Europe and enables the group to meet the demand for genetic services with speed and efficiency, raising the level of care provided to the group’s patients. 
The team at FutureLife believe in a world where everyone has the freedom to create a family and adopt an evidence-based approach to the innovation of treatment strategies, with a mission statement focused on ethics and standards. 

FutureLife is co-owned by CVC and Hartenberg.
www.futurelifegroup.com

Press contacts 

For FutureLife:
Jane Exon
pressoffice@futurelifegroup.com

For Bahçeci Group:
Sevgi Demir
hsdemir@bahceci.com